Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

• Status: Recruiting
• Trial end date: 2022-11-30
• Target enrollment: 0
• Participant gender: All

Summary

A phase II，single arm，open-label study to assess Maintenance Therapy of Chidamide in Patients With Hepatitis B Virus（HBV）Positive Diffuse Large B-cell Lymphoma with complete response after completion of prior chemotherapy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: oubai

Criteria

Inclusion Criteria:

• histopathology confirmed DLBCL，with chronic hepatitis B before treatment

• After systemic treatment, complete response has been achieved and complete response lasted within 1year before enrollment

• The expected chemotherapy was completed and the laboratory indexes returned to normal

• The absolute value of neutrophil ≥ 1.5 × 10 9 / L, platelet count≥ 90 × 10 9 / L, hemoglobin level≥ 90 g / L

• Patients who cannot undergo hematopoietic stem cell transplantation for various reasons

• 18-75 years old, both male and female

• ECOG PS 0-1

• Body weight: male 67 ± 20 kg (47-87 kg), female 55 ± 20 kg (35-75 kg)

• expected survival time ≥3 months

• Voluntary written informed consent prior to trail screening

Exclusion Criteria:

• Pregnant and lactating women and women of childbearing age who are unwilling to take contraceptive measures

• Patients with prolonged QTc interval (male > 450ms, female > 470ms), ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI) within 1 year, congestive heart failure (CHF), and coronary heart disease with symptoms requiring drug treatment

• B-ultrasound showed that the width of the fluid dark area in the pericardial cavity was ≥ 10 mm at the end of diastolic period

• Patients with previous or planned organ transplantation

• Patients receiving symptomatic treatment for early myelotoxicity within 7 days before enrollment

• HBV nucleic acid quantitation > 103 IU / ml

• Patients with active bleeding

• Patients with thrombosis, embolism, cerebral hemorrhage, cerebral infarction and other this kind of diseases or medical history

• Patients with active infection or persistent fever within 14 days before enrollment

• less than 6 weeks after major organ surgery

• Abnormal liver function [total bilirubin > 1.5 times of the upper limit of normal value; ALT / AST > 2.5 times of upper limit of normal value for patients without liver metastasis ; ALT / AST > 5 times of upper limit of normal value for patients with liver metastasis ], abnormal renal function (serum creatinine > 1.5 times of upper limit of normal value)

• Mental disorders/Those who cannot obtain informed consent

• Patients with drug abuse and long-term alcohol abuse that affect evaluation

• The investigator determined not suitable to participate in this study